Manhattan BioSolutions establishes new laboratory space at the JLabs JNJ Innovation incubator in New York City

by Mbio2018|Published November 1, 2018

Manhattan BioSolutions Signs an Option to Exclusive License Agreement with the University at Buffalo to Develop Novel Monoclonal Antibody Targeting a Multiligand Receptor Involved in Inflammatory Responses and Cancer

New York, NY, May 27, 2020 – Manhattan BioSolutions, Inc. (MBS), a biotechnology company focused on the discovery of the next-generation therapies […]

Published May 22, 2023

Manhattan BioSolutions, Inc. Selected to be Featured in New York Pavilion at BIO International Convention

https://www.issuewire.com/manhattan-biosolutions-inc-selected-to-be-featured-in-new-york-pavilion-at-bio-international-convention-1766550010501619 New York City, New York May 22, 2023 (Issuewire.com) – Manhattan BioSolutions, Inc. (“Manhattan Bio”), an emerging biotechnology company developing new classes of […]

Published September 1, 2018

Manhattan BioSolutions has been awarded Phase 1 SBIR Grant from the National Cancer Institute, National Institute Of Health

https://projectreporter.nih.gov/project_info_description.cfm?aid=9623199&icde=51409496&ddparam=&ddvalue=&ddsub=&cr=1&csb=default&cs=ASC&pball= Project Number: 1R43CA228746-01A1 Title: NOVEL RECOMBINANT BCG FOR IMMUNOTHERAPY OF BLADDER CANCER

Published August 23, 2021

EVQLV and Manhattan BioSolutions Announce Grant Award from UB CAT

New York City, New York Jun 29, 2021 (Issuewire.com) – EVQLV, an innovator in developing artificial intelligence to accelerate how biologic therapies reach patients, […]